Table 6 Summary of efficacy according to EGFR sensitizing mutation (common or rare) and common sensitizing EGFR mutation type (exon 19 deletion or L858R) and first-line treatment (EGFR TKI or chemotherapy) used in patients carrying common sensitizing EGFR mutations
From: Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
EGFR sensitizing mutation (n = 132) mutation (n = 131) | Common sensitizing EGFR mutation (n = 112) | |||||
|---|---|---|---|---|---|---|
Type of mutation | First-line treatment | |||||
Endpoint | Common | Rare | Del 19 | L858R | TKI | CT |
Evaluable | 112 | 20 | 82 | 30 | 96 | 16 |
Response, n (%) | ||||||
CR | 3 (3.1) | 0 (0.0) | 2 (2.9) | 1 (3.6) | 3 (3.1) | 1 (6.3) |
PR | 48 (50.0) | 2 (12.5) | 35 (51.5) | 13 (46.4) | 48 (50.0) | 2 (12.5) |
SD | 38 (39.6) | 8 (50.0) | 27 (39.7) | 11 (39.3) | 38 (39.6) | 11 (68.8) |
PD | 7 (7.3) | 6 (37.5) | 4 (5.9) | 3 (10.7) | 7 (7.3) | 2 (12.5) |
ORR, n (%) | 51 (53.1) | 2 (12.5) | 37 (54.4) | 14 (50.0) | 51 (53.1) | 3 (18.8) |
95% CI | 42.7–63.4 | 1.6–38.4 | 41.9–66.5 | 30.6–69.4 | 42.7–63.4 | 4.0–45.6 |
DCR, n (%) | 89 (92.7) | 10 (62.5) | 64 (94.1) | 25 (89.3) | 89 (92.7) | 14 (87.5) |
95% CI | 85.6–97.0 | 35.4–84.8 | 85.6–98.4 | 71.8–97.7 | 85.6–97.0 | 61.7–98.4 |